Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has launched its third podcast episode focused on Lewy body dementia, featuring caregivers who share their experiences and insights. The podcast, moderated by CEO Lisa Ricciardi, highlights key symptoms, preparation for doctor visits, and the challenges faced by caregivers. Lewy body dementias, affecting approximately 1.4 million Americans, include Parkinson’s disease dementia and dementia with Lewy bodies, sharing symptoms such as cognitive impairment and visual hallucinations. The company is conducting a Phase 2 SHIMMER trial for its candidate CT1812, with support from a $30M NIH grant.
- Introduction of the third podcast episode addressing Lewy body dementia, potentially increasing awareness.
- Support for the SHIMMER trial with a significant $30M NIH grant, indicating confidence in the study's importance.
- None.
PURCHASE, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who are also passionate advocates for the second most common and devastating form of dementia. They describe their experiences and journey as caregivers through the difficult process of getting an accurate diagnosis and finding resources and support for their loved ones. In addition, they provide valuable insights on the key symptoms that define Lewy Body dementia, preparing for doctor visits and where to turn for resources and support.
Episode 3: “What if it’s not Alzheimer’s: The Caregiver’s Perspective on Dementia with Lewy Bodies” is moderated by Lisa Ricciardi, Cognition’s chief executive officer, and features a conversation between:
- Norma Loeb
Founder and Executive Director
Lewy Body Dementia Resource Center - Mary Lou Falcone
Founder, M.L. FALCONE, Public Relations
Board member, LBD Resource Center
Author: “I Didn't See It Coming, a Memoir of Love, Loss, and Lewy Body Dementia”
This twenty-minute conversation is presented in three sections:
- Key symptoms and signs of Lewy body dementia
- Preparing for a doctor visit
- Caring for the caregiver
Cognition Therapeutics welcomes comments, questions and feedback on this and other Conversations episodes which may be submitted at conversations@cogrx.com. We’d love to hear your thoughts!
About Lewy body dementias
Lewy body dementias include Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB). PDD and DLB also share a constellation of symptoms including cognitive impairment, Parkinsonian mobility issues, visual hallucinations, and fluctuations of attention, with the timing of the onset of dementia relative to Parkinsonism being the major clinical distinction between DLB and PDD. An estimated 1.4 million Americans are living with Lewy body dementias, accounting for approximately 5
Lewy body dementias are characterized by a build-up of α-synuclein, which forms deposits called Lewy bodies and Lewy dendrites in the brain. Oligomers of α-synuclein are highly toxic and bind to neurons where they impair critical cellular processes, causing synaptic dysfunction and loss. There are currently no disease-modifying treatments approved for these patients.
About the SHIMMER trial
Cognition is conducting the double-blind Phase 2 SHIMMER study (COG1201) in adults with dementia with Lewy bodies (DLB). The clinical trial is designed to enroll 120 individuals between 50 and 80 years of age, who will be randomized to receive a placebo or one of two daily oral doses of CT1812 for six months. In addition to safety, this study will compare changes in cognitive performance, physical activity, and pharmacokinetic and pharmacodynamic biomarkers to baseline measurements. To learn more about the SHIMMER study and site locations please visit www.shimmerDLBstudy.com.
The SHIMMER study is supported by
About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com
Health Care Disclaimer
Our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release and discussed on the podcast, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and expectations regarding Lewy body dementia treatment, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, our ability to secure new (and retain existing) grant funding, our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities Exchange Commission. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact Information:
Cognition Therapeutics, Inc.
info@cogrx.com
Aline Sherwood (media)
Scienta Communications
asherwood@scientapr.com
Daniel Kontoh-Boateng / Rosalyn Christian (investors)
Tiberend Strategic Advisors, Inc.
dboateng@tiberend.com / rchristian@tiberend.com
FAQ
What is the focus of Cognition Therapeutics' latest podcast episode?
What is the SHIMMER trial conducted by Cognition Therapeutics?
How many Americans are affected by Lewy body dementias?
What are some symptoms of Lewy body dementia mentioned in the podcast?
Who moderates the podcast episode on Lewy body dementia?
